Clinical Trial

Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a research study to evaluate the safety of an investigational autologous cell product obtained from participant's own adipose tissue as a possible treatment for Alzheimer disease.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-12-19; most recent amendment 2025-04-01.
Status change: Not Yet Recruiting → Recruiting 2023-08-17
Trial Details
NCT Number NCT05667649
Lead Sponsor Regeneration Biomedical, Inc.
Conditions Alzheimer Disease
Enrollment 18 participants
Start Date 2023-08-14
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-04-04